Who is eligible for clinical trial NCT05568095?

Participants must meet protocol criteria for Advanced Upper Gastrointestinal Tract Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05568095 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-29

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (NCT05568095)

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Arcus Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Who can join: Review the eligibility criteria below.

Location: Research Site — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (168 Sites)

Showing the first 25 of 168 sites.

Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — Santa Monica, California
Research Site — New Haven, Connecticut
Research Site — Washington D.C., District of Columbia
Research Site — Fort Myers, Florida
Research Site — St. Petersburg, Florida
Research Site — Tallahassee, Florida
Research Site — Louisville, Kentucky
Research Site — Louisville, Kentucky
Research Site — New Orleans, Louisiana
Research Site — Boston, Massachusetts
Research Site — Ann Arbor, Michigan
Research Site — Saint Louis Park, Minnesota
Research Site — Mineola, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — Durham, North Carolina
Research Site — Cleveland, Ohio
Research Site — Cleveland, Ohio
Research Site — Columbus, Ohio
Research Site — Mayfield Heights, Ohio
Research Site — Portland, Oregon
Research Site — Nashville, Tennessee
Research Site — Nashville, Tennessee

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Advanced Upper Gastrointestinal Tract Adenocarcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗